Tango Therapeutics Prices Upsized $600 Million Public Offering to Advance Precision Cancer Pipeline
核心洞察
Tango Therapeutics priced an upsized underwritten public offering expected to generate approximately $600 million in gross proceeds, up from the initially proposed $500 million.
The offering includes 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants for an additional 1,833,395 shares at $29.999 each.
J.P. Morgan (搜索), Leerink Partners (搜索), Cantor (搜索), and Stifel (搜索) are serving as joint bookrunning managers, with closing anticipated on or about June 11, 2026.
Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines, announced on June 9, 2026 the pricing of an upsized underwritten public offering expected to generate approximately $600 million in gross proceeds before deducting underwriting discounts, commissions, and offering-related expenses. The offering, which was upsized from the initially proposed $500 million disclosed just one day earlier, underscores strong investor demand for the company's synthetic lethality-based oncology pipeline.
The offering consists of 18,166,667 shares of common stock priced at $30.00 per share, alongside pre-funded warrants to purchase up to 1,833,395 shares of common stock at $29.999 per pre-funded warrant. The pre-funded warrant price reflects the per-share offering price less the $0.001 per share exercise price. All shares and pre-funded warrants are being sold by Tango.
J.P. Morgan (搜索), Leerink Partners (搜索), Cantor (搜索), and Stifel (搜索) are acting as joint bookrunning managers for the offering. Tango has also granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about June 11, 2026, subject to customary closing conditions.
The offering is being conducted pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and made available on the SEC's website.
Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies targeting critical vulnerabilities in cancer. The company describes its approach as one that "starts and ends with patients," aiming to deliver the next generation of precision medicine for cancer treatment. The substantial capital raised through this offering is expected to support the advancement of the company's clinical-stage pipeline and ongoing research efforts.
The company cautioned that forward-looking statements regarding the timing, closing, and proceeds of the offering are subject to risks and uncertainties detailed in its SEC filings, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.